Evaluation of Changes in Peripheric Biomarkers Related to Blood Brain Barrier Damage in Patients with Schizophrenia and Their Correlation with Symptoms
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: The aim of the study was to evaluate the levels of peripheric biomarkers that have been associated with blood brain barrier (BBB) damage in healthy controls and two groups of patients with schizophrenia, those who received typical-atypical antipsychotics and those who received only atypical antipsychotics. Additionally, we sought relationships between these biomarkers and schizophrenia symptoms. Methods: This study was conducted with the inclusion of 41 healthy volunteers and 75 patients with schizophrenia. The biomarkers measured to evaluate BBB injury were as follows: spectrin breakdown product 145 (SBDP145), spectrin breakdown product 150 (SBDP150), ubiquitin carboxy terminal hydrolase L1 (UCHL1), ubiquitin ligase cullin-3 (cullin), occludin and claudin, which were measured via ELISA. Symptoms of patients with schizophrenia were evaluated with the Scale for the Assessment of Positive Symptoms (SAPS), Scale for the Assessment of Negative Symptoms, the Clinical Global Impression Scale (CGI), and the general assessment of functionality (GAF). Results: Compared to controls, SBDP145 (p = 0.022) and cullin (p = 0.046) levels were significantly higher in patients with schizophrenia receiving atypical antipsychotic treatment. SBDP150 levels were lower in the combination treatment group compared to the control group (p = 0.022). Claudin (p = 0.804), occludin (p = 0.058) and UCHL1 (p = 0.715) levels were similar among groups. In recipients of combination treatment, SBDP145 levels were found to be positively correlated with SAPS-total (r = 0.440, p = 0.036) and SAPS-delusions (r = 0.494, p = 0.017) scores. Conclusion: The relationships demonstrated in this study indicate that more comprehensive research is needed to understand whether BBB defects contribute to clinical characteristics in patients with schizophrenia.
Abstract
Objective: The aim of the study was to evaluate the levels of peripheric biomarkers that have been associated with blood brain barrier (BBB) damage in healthy controls and two groups of patients with schizophrenia, those who received typical-atypical antipsychotics and those who received only atypical antipsychotics. Additionally, we sought relationships between these biomarkers and schizophrenia symptoms. Methods: This study was conducted with the inclusion of 41 healthy volunteers and 75 patients with schizophrenia. The biomarkers measured to evaluate BBB injury were as follows: spectrin breakdown product 145 (SBDP145), spectrin breakdown product 150 (SBDP150), ubiquitin carboxy terminal hydrolase L1 (UCHL1), ubiquitin ligase cullin-3 (cullin), occludin and claudin, which were measured via ELISA. Symptoms of patients with schizophrenia were evaluated with the Scale for the Assessment of Positive Symptoms (SAPS), Scale for the Assessment of Negative Symptoms, the Clinical Global Impression Scale (CGI), and the general assessment of functionality (GAF). Results: Compared to controls, SBDP145 (p = 0.022) and cullin (p = 0.046) levels were significantly higher in patients with schizophrenia receiving atypical antipsychotic treatment. SBDP150 levels were lower in the combination treatment group compared to the control group (p = 0.022). Claudin (p = 0.804), occludin (p = 0.058) and UCHL1 (p = 0.715) levels were similar among groups. In recipients of combination treatment, SBDP145 levels were found to be positively correlated with SAPS-total (r = 0.440, p = 0.036) and SAPS-delusions (r = 0.494, p = 0.017) scores. Conclusion: The relationships demonstrated in this study indicate that more comprehensive research is needed to understand whether BBB defects contribute to clinical characteristics in patients with schizophrenia.
참고문헌 (37)
- GBD 2017 Disease and Injury Incidence and Prevalence Collaborators, "Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017 : a systematic analysis for the Global Burden of Disease Study 2017", Lancet, 392, pp.1789~1858 (2018)
- Kahn RS, "Schizophrenia", Nat Rev Dis Primers, 1, pp.15067~ (2015)
- Najjar S, "Neurovascular unit dysfunction and blood-brain barrier hyperpermeability contribute to schizophrenia neurobiology : a theoretical integration of clinical and experimental evidence", Front Psychiatry, 8, pp.83~ (2017)
- Shalev H, "Breaching the blood-brain barrier as a gate to psychiatric disorder", Cardiovasc Psychiatry Neurol, 2009, pp.278531~ (2009)
- Bechter K, "Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders : identification of subgroups with immune responses and blood-CSF barrier dysfunction", J Psychiatr Res, 44, pp.321~330 (2010)
- Titulaer MJ, "Antibodies to NMDA receptor, blood-brain barrier disruption and schizophrenia : a theory with unproven links", Mol Psychiatry, 19, pp.1054~ (2014)
- Pollak TA, "The blood-brain barrier in psychosis", Lancet Psychiatry, 5, pp.79~92 (2018)
- Yan XX, "Spectrin breakdown products(SBDPs)as potential biomarkers for neurodegenerative diseases", Curr Transl Geriatr Exp Gerontol Rep, 1, pp.85~93 (2012)
- Bakhshi K, "The neuropathology of schizophrenia : a selective review of past studies and emerging themes in brain structure and cytoarchitecture", Neuroscience, 303, pp.82~102 (2015)
- Greene C, "Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia", Mol Psychiatry, 23, pp.2156~2166 (2018)
- Lepeta K, "Matrix metalloproteinase-9 as a novel player in synaptic plasticity and schizophrenia", Schizophr Bull, 41, pp.1003~1009 (2015)
- Pan R, "Blood occludin level as a potential biomarker for early blood brain barrier damage following ischemic stroke", Sci Rep, 7, pp.40331~ (2017)
- Jain P, "Detection of alpha II-spectrin breakdown products in the serum of neonates with congenital heart disease", Pediatr Crit Care Med, 15, pp.229~235 (2014)
- Reeves TM, "Proteolysis of submembrane cytoskeletal proteins ankyrin-G and αII-spectrin following diffuse brain injury : a role in white matter vulnerability at Nodes of Ranvier", Brain Pathol, 20, pp.1055~1068 (2010)
- Loryan I, "In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions : link to spatial receptor occupancy", Mol Psychiatry, 21, pp.1527~1536 (2016)
- Andreasen NC, "Methods for assessing positive and negative symptoms", Mod Probl Pharmacopsychiatry, 24, pp.73~88 (1990)
- Erkoç Ş, "The reliability and validity of scale for the assessment of the positive symptoms", Düşünen Adam, 4, pp.20~24 (1991)
- Erkoç Ş, "The reliability and validity of scale for the assessment of the negative symptoms", Düşünen Adam, 4, pp.16~19 (1991)
- Guy W, "ECDEU assessment manual for psychopharmacology", pp.217~222 (1976), U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration
- Grootenboer EM, "Reliability and validity of the Global Assessment of Functioning Scale in clinical outpatients with depressive disorders", J Eval Clin Pract, 18, pp.502~507 (2012)
- Mondello S, "α II-spectrin breakdown products(SBDPs) : diagnosis and outcome in severe traumatic brain injury patients", J Neurotrauma, 27, pp.1203~1213 (2010)
- Kitamura N, "Asymmetrical changes in the fodrin alpha subunit in the superior temporal cortices in schizophrenia", Biol Psychiatry, 43, pp.254~262 (1998)
- Murakami N, "Association study of a polymorphism of nonerythroid alpha-spectrin gene with schizophrenia", Am J Med Genet, 88, pp.291~293 (1999)
- Cetin I, "Increased serum levels of spectrin degradation products in patients with schizophrenia", Turk J Biochem, 43, pp.22~29 (2018)
- Kealy J, "Blood-brain barrier regulation in psychiatric disorders", Neurosci Lett, 726, pp.133664~ (2020)
- Cai HQ, "Increased macrophages and changed brain endothelial cell gene expression in the frontal cortex of people with schizophrenia displaying inflammation", Mol Psychiatry, 25, pp.761~775 (2020)
- Greene C, "Blood-brain barrier associated tight junction disruption is a hallmark feature of major psychiatric disorders", Transl Psychiatry, 10, pp.373~ (2020)
- Liebner S, "Functional morphology of the blood-brain barrier in health and disease", Acta Neuropathol, 135, pp.311~336 (2018)
- Benz F, "Low wnt", b-catenin signaling determines leaky vessels in the subfornical organ and affects water homeostasis in mice, 2019, pp.8, e43818~
- Omidinia E, "Polymorphism of the CLDN5 gene and schizophrenia in an Iranian population", Iran J Public Health, 43, pp.79~83 (2014)
- Ciechanover A, "Ubiquitin-mediated proteolysis : biological regulation via destruction", Bioessays, 22, pp.442~451 (2000)
- Vawter MP, "Application of cDNA microarrays to examine gene expression differences in schizophrenia", Brain Res Bull, 55, pp.641~650 (2001)
- Middleton FA, "Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia", J Neurosci, 22, pp.2718~2729 (2002)
- Altar CA, "Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts", Biol Psychiatry, 58, pp.85~96 (2005)
- Müller N, "Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients : relationship to negative symptomatology", Schizophr Res, 14, pp.223~228 (1995)
- Bousman CA, "Positive symptoms of psychosis correlate with expression of ubiquitin proteasome genes in peripheral blood", Am J Med Genet B Neuropsychiatr Genet, 153B, pp.1336~1341 (2010)
- Elmorsy E, "Adverse effects of antipsychotics on micro-vascular endothelial cells of the human blood-brain barrier", Brain Res, 1583, pp.255~268 (2014)
